Your browser doesn't support javascript.
loading
Latent Class Analysis Reveals, in patient profiles, COVID-19-related better prognosis by calcifediol treatment than glucocorticoids.
Entrenas-Castillo, Marta; Entrenas-Costa, Luis Manuel; Pata, María P; Gamez, Bernabe Jurado; Muñoz-Corroto, Cristina; Gómez-Rebollo, Cristina; Mira-Padilla, Estefanía; Bouillon, Roger; Quesada-Gomez, Jose Manuel.
Afiliación
  • Entrenas-Castillo M; Hospital QuironSalud Córdoba, Córdoba 14004, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba 14004, Spain.
  • Entrenas-Costa LM; Hospital QuironSalud Córdoba, Córdoba 14004, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba 14004, Spain; Unidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, Córdoba 14004, Spain.
  • Pata MP; Biostatech, Santiago de Compostela 15782, Spain.
  • Gamez BJ; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba 14004, Spain; Unidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, Córdoba 14004, Spain.
  • Muñoz-Corroto C; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba 14004, Spain; Unidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, Córdoba 14004, Spain.
  • Gómez-Rebollo C; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba 14004, Spain; Unidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, Córdoba 14004, Spain.
  • Mira-Padilla E; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba 14004, Spain; Unidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, Córdoba 14004, Spain.
  • Bouillon R; Laboratory of Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven 3000, Belgium. Electronic address: roger.bouillon@kuleuven.be.
  • Quesada-Gomez JM; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba 14004, Spain; Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Reina Sofía, Córdoba 14004, Spain; CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid 2802
J Steroid Biochem Mol Biol ; 245: 106609, 2024 Aug 31.
Article en En | MEDLINE | ID: mdl-39218235
ABSTRACT
Calcifediol and glucocorticoids have been repositioned for the treatment of COVID-19 and may reduce severity, the need for intensive care unit admission and death.

OBJECTIVE:

to identify class or profiles of patients hospitalized and treated with COVID-19 pneumonia using latent class clustering methods to assess the clinical and prognostic relevance of the resulting patients' profiles. Poor prognosis was defined as death or need for ICU admission, good prognosis, the opposite. With special interest in differential responses to calcifediol.

SETTING:

Reina Sofia University Hospital, Córdoba Spain. PATIENTS Retrospective observational cohort study of patients admitted for COVID-19. CLINICALTRIALS gov public database (NCT05819918). INCLUSION CRITERIA (i) Age ≥ 18 and ≤ 90 years, (ii) Pneumonia characterized by the presence of infiltrates on chest X-ray or CT scan, (iii) SARS-CoV-2 infection, confirmed, and (iv) CURB Scale 65 >1.

DESIGN:

Latent class analysis, for obtaining homogeneous clusters, without specifying a priori the belonging group, and selecting the optimal number of clusters by minimizing information criteria. Evaluating the differences between groups for each variable by means of chi-square, Fisher's exact test and Kruskal-Wallis test.

RESULTS:

707 patients hospitalized from 10 March 2020 until 4 March 2022 were included. For the treatment variable, differences were found between class 3 (60 % treated with calcifediol only) and classes 1 (less than 1 % calcifediol only vs. 82 % treated with both), 2 (less than 1 % calcifediol only vs. 82 % treated with both) and 4 (1 % calcifediol only vs. 84 % treated with both). Class 3, (60 % with calcifediol), had a significantly better prognosis compared to patients treated with glucocorticoids alone (OR 15.2, 95 % CI [3.73-142], p<0.001) or no treatment (OR 7.38, 95 % CI [2.63-30.2], p<0.001).

CONCLUSIONS:

our real-life study shows that calcifediol treatment significantly reduces the need for ICU admission and improved prognosis in patients hospitalized for COVID-19 pneumonia, especially in the profile of patients receiving it without glucocorticoids.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Steroid Biochem Mol Biol Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Steroid Biochem Mol Biol Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido